Bulk Drug Import Quality Reports May Be Required From U.S. Firms
Executive Summary
Pharmaceutical manufacturers may be required to notify FDA when they receive bulk drugs of poor quality, FDA Associate Commissioner for Regulatory Affairs Dennis Baker told a House subcommittee hearing June 8.
You may also be interested in...
FDA Analyzing Non-Inspected Foreign Firms Which Are Named in NDAs
FDA's next step in analyzing data from the Operational and Administrative System for Import Support will be to identify non-inspected foreign drug firms referenced in approved human or animal drug applications.
FDA Analyzing Non-Inspected Foreign Firms Which Are Named in NDAs
FDA's next step in analyzing data from the Operational and Administrative System for Import Support will be to identify non-inspected foreign drug firms referenced in approved human or animal drug applications.
Jeffords Rx Re-Importation Bill Gains Sen. Gorton's Support
Sen. Jeffords' (R-Vt.) prescription drug re-importation bill has gained the support of another border-state Republican: Sen. Gorton of Washington.